CCM
GILD icon

Copeland Capital Management’s Gilead Sciences GILD Stock Holding History

Copeland Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27
Closed -$2K – 281
2020
Q3 		$2K Hold
27
– – ﹤0.01% 233
2020
Q2 		$2K Buy
+27
New +$2.07K ﹤0.01% 224
2019
Q3 		– Sell
-21
Closed -$1K – 307
2019
Q2 		$1K Hold
21
– – ﹤0.01% 294
2019
Q1 		$1K Hold
21
– – ﹤0.01% 251
2018
Q4 		$1K Buy
+21
New +$1.47K ﹤0.01% 260

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Copeland Capital Management's GILD Position: Q4 2020 in Review

Copeland Capital Management sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 27 shares — an estimated $2K sold.

Copeland Capital Management first reported a position in GILD in Q4 2018 and held it in 5 quarters. The position peaked at $2K in Q3 2020. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

  • Copeland Capital Management reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
  • Copeland Capital Management sold 27 Gilead Sciences shares in Q4 2020, an estimated $2K.
  • Copeland Capital Management first reported a position in Gilead Sciences in Q4 2018 and held it in 5 quarters.
  • Copeland Capital Management's Gilead Sciences position peaked at $2K in Q3 2020.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Copeland Capital Management's 13F filing for Q4 2020, filed 27 Jan 2021.